Project Description

Jericho Sciences develops novel antiviral therapeutics and personalized diagnostics to specifically address the limitations of current combination antiretroviral therapy (cART) in the clinical management of HIV-1 infection, with the goal of reducing the persistent reservoir of latently-infected cells, toward a functional “cure.”